Genmab A (GMAB) Total Current Liabilities (2019 - 2026)

Genmab A has reported Total Current Liabilities for 6 years, with the latest figure at $1.2 billion in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities changed N/A year-over-year to $1.2 billion; the trailing twelve-month figure through Mar 2026 stood at $1.2 billion (changed N/A YoY), and the FY2025 full-year result was $1.4 billion, up 91.8% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $1.2 billion, down from $1.4 billion in the prior quarter.
• The five-year high for Total Current Liabilities was $1.4 billion in Q4 2025, with the low at $368.0 million in Q4 2023.
• Historically, Total Current Liabilities has averaged $847.8 million across 4 years, with a median of $742.5 million in 2024.
• Annual changes were most pronounced in 2024 — Total Current Liabilities surged 102.17% — and 2025, when it soared 91.8%.
• Genmab A's Total Current Liabilities stood at $368.0 million in 2023, then surged by 102.17% to $744.0 million in 2024, then soared by 91.8% to $1.4 billion in 2025, then decreased by 17.45% to $1.2 billion in 2026.
• The last three Total Current Liabilities figures came in at $1.2 billion (Q1 2026), $1.4 billion (Q4 2025), and $741.0 million (Q3 2025), per Business Quant data.